cox 189 has been researched along with bilirubin in 1 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (bilirubin) | Trials (bilirubin) | Recent Studies (post-2010) (bilirubin) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 25,921 | 1,337 | 5,871 |
| Protein | Taxonomy | cox 189 (IC50) | bilirubin (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3884 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.3183 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalbag, J; Lasseter, K; Milosavljev, S; Oberstein, S; Rordorf, C; Yeh, CM | 1 |
1 other study(ies) available for cox 189 and bilirubin
| Article | Year |
|---|---|
No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.
Topics: Administration, Oral; Area Under Curve; Bilirubin; Case-Control Studies; Cyclooxygenase Inhibitors; Diclofenac; Drug Administration Schedule; Female; Half-Life; Humans; Liver Diseases; Male; Middle Aged; Organic Chemicals; Prothrombin Time; Serum Albumin; Switzerland; Tablets; Time Factors; Treatment Outcome | 2004 |